Acceleron Pharma Reports Second Quarter 2016 Financial and Operational Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acceleron Pharma (XLRN) Misses Q2 EPS by 9c
August 4, 2016 8:09 AM EDTAcceleron Pharma (NASDAQ: XLRN) reported Q2 EPS of ($0.59), $0.09 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $3.2 million versus the consensus estimate of $3.77 million.
Cash, cash equivalents and investments as of June 30, 2016 were $262.7 million. As of December 31, 2015 the Company had... More
